Login to Your Account

Deals And M&A NEWS

As company backers await data from the phase I trial with CUDC-907, due in June at the American Society of Clinical Oncology (ASCO), Curis Inc. signed an immuno-oncology deal that could be worth more than $100 million to Aurigene Discovery Technologies Ltd.

Just last week, Celgene Corp.'s head of business development, George Golumbeski, told a packed breakout session at the annual J.P. Morgan Healthcare Conference in San Francisco that the firm's long-term pipeline "can never be big enough."

DUBLIN – Roche Holding AG continued its new year shopping spree, putting down an initial €120 million (US$138 million) to acquire Trophos SA, with up to €350 million more to come in milestone payments.
More Deals And M&A Headlines

Cast Your Vote

Has biotech’s bubble burst?: